2151 related articles for article (PubMed ID: 18327401)
1. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
2. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
3. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
Farias WR; Nazareth RA; Mourão PA
Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
[TBL] [Abstract][Full Text] [Related]
5. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
[TBL] [Abstract][Full Text] [Related]
6. Structure and anticoagulant activity of a sulfated galactan from the red alga, Gelidium crinale. Is there a specific structural requirement for the anticoagulant action?
Pereira MG; Benevides NM; Melo MR; Valente AP; Melo FR; Mourão PA
Carbohydr Res; 2005 Sep; 340(12):2015-23. PubMed ID: 16023626
[TBL] [Abstract][Full Text] [Related]
7. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
Fonseca RJ; Santos GR; Mourão PA
Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
[TBL] [Abstract][Full Text] [Related]
8. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
9. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
11. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
12. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
13. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
15. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
17. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
20. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
